Clinical Trial Update: Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older [Phase 2]

View source ↗

Summary

Phase 2 study of a Sanofi Pasteur respiratory syncytial virus vaccine candidate in adults aged 60 years and older has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine candidate formulation

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers | Phase 2 | Status: COMPLETED